Rosacea
Conditions
Interventions
Conventional dose group:Oral paroxetine, 25mg Qd, Four Months
Low dose group:Oral (paroxetine 12.5mg + placebo 12.5mg), Qd, Four Months.
Control group:Oral placebo, 25mg, Qd, Four Months
Sponsors
Xiangya Hospital Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Definition of intractable rosacea: after 12 weeks of oral administration of conventional drugs such as doxycycline, with or without other treatments (topical drugs /IPL, etc.), patients with treatment resistance (erythema not reduced by 1 grade or erythema greater than or equal to 3 degrees), or patients with frequent recurrence during 12 weeks of treatment. 2. And signed the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1. Age 65 years; 2. Pregnant and breastfeeding women and with recent pregnancy plans; 3. With nasal hyperplasia hypertrophy rosacea patients; 4. Patients with moderate or severe liver, kidney, lung or blood and other systemic diseases; 5. Suspected gastric acid deficiency, acute or chronic gastrointestinal ulcer or duodenal surgery (cannot absorb drugs); 6. History of mental illness; 7. Paroxetine allergy; 8. Patients with oral amine oxidase inhibitors (such as phenylethylhydrazine, seligilan, etc.); 9. Topical treatment was given within 2 weeks, systemic treatment with common drugs within 4 weeks or isotretinoic acid within 6 months; 10. Combined with other facial skin diseases (such as seborrheic dermatitis, eczema, etc.) or the facial manifestations of other diseases (such as dermatomyositis, systemic lupus erythematosus); 11. Patients who are not expected to follow up; 12. Participants in any clinical trial within one month; 13. Other ineligible conditions were considered by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Erythema Assessment Effective Improvement Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rosacea Clinical Symptom Severity Assessment (Patient Self Assessment);Rating of existing skin lesions (physician evaluation);Flushing Assessment tool (patient evaluation) score;Skin Life Quality Index (DLQI) Questionnaire Score;Depression Anxiety Stress Scale (DASS-21) Score;Facial photographs ;VISIA facial imaging changes; | — |
Countries
China
Contacts
Public ContactBen Wang
Dermatology Hospital of Central South University Xiangya Hospital
Outcome results
None listed